We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

139 hedge funds and large institutions have $499M invested in Karyopharm Therapeutics in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 46 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more call options, than puts

Call options by funds: $12M | Put options by funds: $4.09M

44% more capital invested

Capital invested by funds: $347M → $499M (+$152M)

0.97% more ownership

Funds ownership: 4.78% → 5.75% (+0.97%)

7% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 28

9% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 46

3% less funds holding

Funds holding: 143 → 139 (-4)

Holders
139
Holders Change
-4
Holders Change %
-2.8%
% of All Funds
2.19%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
26
Increased
42
Reduced
46
Closed
28
Calls
$12M
Puts
$4.09M
Net Calls
+$7.88M
Net Calls Change
+$13.6M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$45.3M
2
CC
Commodore Capital
New York
+$29.6M
3
ITP
Iron Triangle Partners
Connecticut
+$16.6M
4
Morgan Stanley
Morgan Stanley
New York
+$14.5M
5
Bank of America
Bank of America
North Carolina
+$7.16M

Top Sellers

Rank Fund Capital Flow
1
Alkeon Capital Management
Alkeon Capital Management
New York
-$12.6M
2
BlackRock
BlackRock
New York
-$8.23M
3
LOAMS
Lombard Odier Asset Management (Switzerland)
Switzerland
-$7.33M
4
FCM
Frontier Capital Management
Massachusetts
-$3.37M
5
CSS
Cubist Systematic Strategies
Connecticut
-$3.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
PFGIA
151
Patriot Financial Group Insurance Agency
Massachusetts
– -$249K -2,583 Closed
SCA
152
Spearhead Capital Advisors
Florida
– -$222K -2,297 Closed
EGM
153
Engineers Gate Manager
New York
– -$181K -1,880 Closed
BC
154
Bridgefront Capital
Texas
– -$157K -1,626 Closed
SG Americas Securities
155
SG Americas Securities
New York
– -$152K -1,581 Closed
PCM
156
Prelude Capital Management
New York
– -$135K -1,400 Closed
NSIM
157
North Star Investment Management
Illinois
– -$129K -1,333 Closed
Assenagon Asset Management
158
Assenagon Asset Management
Luxembourg
– -$125K -1,291 Closed
FRM
159
Fox Run Management
Connecticut
– -$99K -1,030 Closed
GCM
160
Graham Capital Management
Connecticut
– -$81K -841 Closed
Marshall Wace
161
Marshall Wace
United Kingdom
– -$57K -600 Closed
Belvedere Trading
162
Belvedere Trading
Illinois
– -$44K -358 Closed
PA
163
Parallel Advisors
California
– -$2K -22 Closed
EI
164
Ellevest Inc
New York
– +$249 +2 New
QC
165
Quent Capital
New York
– +$249 +2 New
3 4 5 6
7

KPTI Hedge Fund Activity: Q1 2022 in Review

139 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2022, worth a combined $499M — up 44% from $347M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of KPTI and 26 opened new positions — a net loss of 2 holders — while 46 trimmed existing stakes and 42 added.

The largest buyer was State Street, adding an estimated $45.3M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $12.6M sold.

  • 139 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2022, down from 143 in Q4 2021.
  • Funds reported $499M of Karyopharm Therapeutics stock for Q1 2022, up 44% quarter-over-quarter.
  • 26 funds opened new Karyopharm Therapeutics positions in Q1 2022 and 28 closed out, a net change of -2 holders.
  • The largest Karyopharm Therapeutics buyer in Q1 2022 was State Street, an estimated $45.3M added.
  • The largest Karyopharm Therapeutics seller in Q1 2022 was Alkeon Capital Management, an estimated $12.6M sold.

Based on aggregated 13F filings for Q1 2022.